Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ADAM CUKER

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1457414625
CMS profile
66131
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$15,277.50

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
CSL Behring $13,235.00 1
PFIZER INC. $2,000.00 1
SOBI, INC $42.50 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ADAM CUKER

NPI 1457414625 · CMS profile ID 66131

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457414625?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ADAM CUKER, NPI 1457414625, CMS profile ID 66131. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457414625?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ADAM CUKER, NPI 1457414625, CMS profile ID 66131. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457414625?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ADAM CUKER, NPI 1457414625, CMS profile ID 66131, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1457414625?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $15,277.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CSL Behring $13,235.0003/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134642983 CMS
PFIZER INC. $2,000.0003/05/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131628694 CMS
SOBI, INC $42.5001/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141415400 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12.75 1
PY2020 $5,476.41 4
PY2021 $149.85 3
PY2022 $6,450.67 2
PY2023 $9,841.78 5
PY2024 $15,277.50 3
PY2025 $563.77 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,808.70 6
PY2025 Principal investigator $194,094.24 21
PY2024 Recipient $6,318.06 14
PY2024 Principal investigator $245,493.12 25
PY2023 Recipient $5,740.00 5
PY2023 Principal investigator $59,748.12 24
PY2022 Recipient $4,025.00 1
PY2022 Principal investigator $20,806.59 12
PY2021 Principal investigator $214,306.19 31
PY2020 Recipient $8,596.00 5
PY2020 Principal investigator $48,312.86 14
PY2019 Recipient $1,499.17 2
PY2019 Principal investigator $67,054.68 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $4,050.00 12/27/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PFIZER C037 FIELD STUDY No dispute reported 06/30/2026 832533343
Principal investigator 1 PFIZER INC. $972.14 12/24/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832574559
Principal investigator 1 PFIZER INC. $1,207.53 11/23/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832895195
Principal investigator 1 BIOVERATIV THERAPEUTICS INC. $393.00 11/10/2021 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX No dispute reported 06/30/2026 838655789
Principal investigator 1 BIOVERATIV THERAPEUTICS INC. $2,350.00 11/10/2021 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX No dispute reported 06/30/2026 838655791
Principal investigator 1 PFIZER INC. $1,944.28 10/21/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832895697
Principal investigator 1 PFIZER INC. $1,272.47 10/08/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832856201
Principal investigator 1 Novo Nordisk AS $1,200.00 08/25/2021 Non-covered Recipient Entity
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
NN7415-4322 No dispute reported 06/30/2026 811475171
Principal investigator 1 Novo Nordisk AS $1,000.00 08/25/2021 Non-covered Recipient Entity
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
NN7415-4322 No dispute reported 06/30/2026 811475181
Principal investigator 1 Novo Nordisk AS $500.00 08/25/2021 Non-covered Recipient Entity
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
NN7415-4322 No dispute reported 06/30/2026 811476707
Principal investigator 1 PFIZER INC. $3,644.51 08/21/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832755973
Principal investigator 1 PFIZER INC. $24,866.14 07/14/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832901317
Principal investigator 1 PFIZER INC. $1,272.47 07/02/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832884169
Principal investigator 1 PFIZER INC. $376.09 07/01/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832788373
Principal investigator 1 PFIZER INC. $3,752.47 06/23/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832844843
Principal investigator 1 SANOFI US SERVICES INC. $2,350.00 06/10/2021 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX No dispute reported 06/30/2026 838653687
Principal investigator 1 SANOFI US SERVICES INC. $393.00 06/10/2021 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX No dispute reported 06/30/2026 838653689
Principal investigator 1 PFIZER INC. $3,906.98 06/05/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832876271
Principal investigator 1 PFIZER INC. $82,535.48 05/25/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832691965
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,038.00 05/20/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A PHASE II OPEN LABEL PROSPECTIVE SINGLE ARM STUDY TO ASSESS ABILITY OF ELTROMBOPAG TO INDUCE SUSTAINED REMISSION IN SUBJECTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST LINE STEROIDS N N No dispute reported 06/30/2026 800611849
Principal investigator 1 PFIZER INC. $31,607.36 05/07/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832793187
Principal investigator 1 PFIZER INC. $526.50 04/09/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
AN OPENLABEL NONINVESTIGATIONAL PRODUCT MULTICENTER LEADIN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SELECTED SAFETY DATA OF FACTOR IX FIX PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS FIXC2 WHO ARE NEGATIVE FOR NEUTRALIZING ANTIBODIES NAB TO ADENOASSOCIATED VIRUS VECTOR AAVSPARK100 No dispute reported 06/30/2026 832714051
Principal investigator 1 PFIZER INC. $2,737.31 04/09/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832903615
Principal investigator 1 PFIZER INC. $244.07 03/31/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832895471
Principal investigator 1 PFIZER INC. $1,272.47 03/24/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832895687
Principal investigator 1 PFIZER INC. $3,913.09 03/05/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832779029
Principal investigator 1 PFIZER INC. $526.50 02/24/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
AN OPENLABEL NONINVESTIGATIONAL PRODUCT MULTICENTER LEADIN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SELECTED SAFETY DATA OF FACTOR IX FIX PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS FIXC2 WHO ARE NEGATIVE FOR NEUTRALIZING ANTIBODIES NAB TO ADENOASSOCIATED VIRUS VECTOR AAVSPARK100 No dispute reported 06/30/2026 832848329
Principal investigator 1 PFIZER INC. $12,297.68 02/23/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832830947
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 01/26/2021 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX No dispute reported 06/30/2026 838661083
Principal investigator 1 SANOFI US SERVICES INC. $896.00 01/26/2021 Covered Recipient Teaching Hospital
Hospital Of The Univ Of Penna
ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX No dispute reported 06/30/2026 838661085
Principal investigator 1 PFIZER INC. $14,260.65 01/12/2021 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
PHASE 3 OPEN LABEL SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF06838435 RAAVSPARK100HFIXPADUA IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B FIXC LT2 BENEGENE2 No dispute reported 06/30/2026 832709243